NanoViricides, Inc. is developing NV-387, a broad-spectrum antiviral drug that targets viral infections and reduces cancer resurgence via anti-inflammatory effects like IL-6.
3 reports, 1 independent
Updated Aug 18
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NanoViricides, Inc. is developing NV-387, a broad-spectrum antiviral drug that targets viral infections and reduces cancer resurgence via anti-inflammatory effects like IL-6.
How it developed
Newest first. Tap a step to see who reported it.- NanoViricides, Inc. is developing NV-387 for MPox treatment to address the continuing epidemic in Africa.Sub-event
NV-387 is being investigated as a broad-spectrum antiviral with potential applications in mitigating cancer resurgence linked to viral infections and IL-6.1 source
NV-387 development can be accelerated under US FDA programs.1 source
Coverage
Newest first; wire copies grouped- ACCESS NewswireA Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoVir
- ACCESS NewswireMeasles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded c
- ACCESS NewswireNanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value SHE